Drug profile · INN
ustekinumab-aekn
SELARSDI
ustekinumab-aekn (SELARSDI) is a interleukin-12 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ustekinumab-aekn
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ustekinumab-aekn (SELARSDI) is a interleukin-12 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-12 inhibitor
Primary target: Interleukin-12
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ustekinumab-aekn?
ustekinumab-aekn (SELARSDI) is a interleukin-12 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ustekinumab-aekn?
SELARSDI is a marketed brand name for ustekinumab-aekn. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ustekinumab-aekn?
ustekinumab-aekn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.